Saint Therapeutics is a clinical-stage regenerative medicine company advancing peptide-based therapies designed to improve wound healing, tissue repair, and regeneration. Its lead program, SLI-F06, is a Fibromodulin-derived synthetic peptide with the potential to shift wound care from reactive scar management toward biologically targeted prevention.